Article Sidebar
Published:
Mar 6, 2013DOI:
10.4314/tjpr.v12i1.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Preparation, Characterisation and <i>In Vivo<i> Evaluation of Silybin Nanoparticles for the Treatment of Liver Fibrosis
Abstract
Purpose: To formulate and characterize nanoparticles containing silybin, and evaluate their activity against carbon tetrachloride (CCl4)-induced liver toxicity.
Methods: Silybin nanoparticles were formulated by o/w emulsion solvent evaporation technique using poly-å-caprolactone as polymer. Four different nanoparticle formulations (NP1, NP2, NP3 and NP4) were prepared by varying the drug/polymer ratio. The particles were characterized for particle size, drug content and in vitro drug release. The pharmacokinetics and pharmacodynamics of the silybin formulations in male Wistar rats were evaluated following i.v. administration, using silybin solution as
reference. The hepatoprotective activity of the formulations was also determined in a CCl4-treated rat model.
Results: Silybin nanoparticles were successfully prepared using o/w emulsion solvent evaporation technique. The nanoparticles sustained the release of the drug both in vitro and in vivo for up to 10 days and offered better pharmacokinetic properties than the free drug itself. Intravenous nanoparticulate administration reversed serum liver enzyme levels by 95 % compared to only 50 % for the drug solution.
Conclusion: The developed silybin nanoparticles showed superior pharmacokinetic properties and hepatoprotective activity to silybin solution.
Keywords: Silybin, Nanoparticles, Pharmacokinetics, Pharmacodynamics, Hepatoprotective activity.
